Articles
10 June 2009
Vol. 2 No. 13: It’s time to take care of T-Cell Lymphomas Bologna, Italy, 22-24 October 2006
https://doi.org/10.4081/hmr.v2i13.485

Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
272
Views
253
Downloads

Authors

C Querfeld
support@pagepress.org
TM Kuzel
J Guitart
ST Rosen
Lenalidomide 3-(4’aminoisoindo lin-1’-one)-1-piperidine-2, 6-dio ne (Revlimid®) is the lead compound in a new class of agents which are known as the immunomodulatory drugs.1 Lenalidomide has a similar chemical structure to thalidomide. Both drugs have a comparable in vitro profile; however, lenalidomide is more potent.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(13). https://doi.org/10.4081/hmr.v2i13.485